Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.37 |
| ▸ | MME | P08473 | 3/20 | 0.37 |
| ▸ | MC4R | P32245 | 3/20 | 0.36 |
| ▸ | MC5R | P33032 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752162 | 0.84 | CCKBR (0.47) | CCKBR | |
| SCHEMBL489833 | 0.83 | LTB4R2 (0.45) | AGTR1MME | |
| SCHEMBL3743922 | 0.81 | MME (0.44) | AGTR1MMEMC4RMC5RMC3R | |
| SCHEMBL489652 | 0.80 | MME (0.43) | AGTR1MME | |
| SCHEMBL1282882 | 0.79 | MME (0.41) | AGTR1MMEMC4RMC5RMC3R | |
| SCHEMBL489321 | 0.79 | AGTR1 (0.43) | AGTR1MME | |
| SCHEMBL489197 | 0.78 | AGTR1 (0.39) | AGTR1MME | |
| SCHEMBL489583 | 0.77 | CCKBR (0.49) | CCKBR | |
| SCHEMBL839267 | 0.77 | MME (0.43) | AGTR1MME | |
| SCHEMBL839266 | 0.77 | MME (0.43) | AGTR1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834041-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | AGTR1 1/4885MME 5/4885MC4R 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.